UPDATE ON RESEARCH IN PARKINSON S DISEASE
|
|
- Emily Welch
- 5 years ago
- Views:
Transcription
1 UPDATE ON RESEARCH IN PARKINSON S DISEASE Charles H. Adler, M.D., Ph.D. Professor of Neurology Mayo Clinic College of Medicine Co-Principal Investigator Arizona Parkinson s Disease Consortium
2 Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) Collaboration: Mayo, BSHRI, BNI Find biomarkers to predict who will develop PD and who will develop dementia in PD Correlation studies of brain and other tissue with PD and other movement disorders (essential tremor, restless legs syndrome, PSP, etc)
3 Biomarkers (Biological Markers) for PD Disease predictor: earlier diagnosis may lead to disease-modifying treatments Disease outcome measure: monitoring disease progression Diagnostic tissue biomarker may replace autopsy for confirming/validating diagnosis for genetic/epidemiology/biomarker/treatment
4 Natural History of Parkinson s Disease Dopamine Neuron Function Prediagnostic Motor Phase Diagnosis Time Adapted from Marek and Jennings Neurol 09
5 Initiate Treatment Dopamine Neuron Function Prediagnostic Motor Phase Diagnosis Treatment Time Adapted from Marek and Jennings Neurol 09
6 Prephysiologic PD Dopamine Neuron Function Genetic predisposition LRRK2, DJ-1, parkin, PINK1, GBA, SYN triplication Prediagnostic Motor PD Diagnosis Time
7 Preclinical PD Dopamine Neuron Function Prephysiologic Phase Genetic vulnerability Preclinical Phase Imaging Tissue test Prediagnostic Motor Phase Diagnosis Time
8 Premotor PD Dopamine Neuron Function Prephysiologic Phase Genetic vulnerability Preclinical Phase Imaging Tissue Premotor Phase Hyposmia RBD Autonomic Depression/anxiety Prediagnostic Motor Phase Diagnosis Time
9 High Risk Biomarker Identification and Drug Modifying Treatment Initiation Dopamine Neuron Function Prephysiologic Phase Premotor Phase Biomarker found treatment initiated Prediagnostic Motor Phase Diagnosis Time
10 AZSAND Evaluations Annual evaluations: Movement disorder exam Cognitive test battery General neurological exam/medical evaluation Sleep, autonomic, bowel movement questionnaires Every other year: EEG/EMG testing on a subset Every 3 rd year: Smell test (UPSIT-40)
11 So, what do we do with all this information?
12
13 Positive Predictive Value for ProbPD seen at First Visit ProbPD N 97 Female 32 (33%) Age at Visit 76.8 (7.5) Age at Death 80.6 (7.0) Duration of PD Symptoms at Visit 11.0 (6.6) Duration of PD Symptoms at Death 14.8 (6.9) Neuropathologically Confirmed PD 80 (82%) 95% CI 73% to 89% Adler et al. Neurol 14
14 PPV for ProbPD Divided by Disease Duration at First Visit ProbPD ProbPD <5 y ProbPD 5 y N Female 32 (33%) 4 (27%) 28 (34%) Age at Visit 76.8 (7.5) 78.4 (6.7) 76.6 (7.7) Age at Death 80.6 (7.0) 82.4 (6.0) 80.3 (7.1) Duration of PD Symptoms at Visit 11.0 (6.6) 2.4 (1.2) 12.6 (6.0) Duration of PD Symptoms at Death 14.8 (6.9) 6.4 (3.4) 16.3 (6.3) Neuropathologically Confirmed PD 80 (82%) 8 (53%) 72 (88%) 95% CI 73% to 89% 27% to 79% 79% to 94%
15 Conclusions An early clinical diagnosis of PD (pre-treatment or within 5 yrs. of onset) is inaccurate Important for RESEARCH on early PD including treatment trials, biomarker, genetic, and epidemiological studies Does NOT change what your doctor does for you!! Even if not PD most of the subjects had a neurologic disease that would need same Rx
16 Non-Motor Symptoms in PD Predate Motor Symptoms Hyposmia or Anosmia Visual Changes Sleep Disorders Neuropsychiatric Autonomic Dysfunction Cognitive Impairment Advanced PD Sleep Disorders Cognitive Impairment Neuropsychiatric Autonomic Dysfunction Sensory Disorders Impulse Control Disorders
17 Smell Test, Sleep Questionnaire, Autonomic Questionnaire We have performed tests on >1,200 subjects Multiple papers and presentations
18
19 Sense of Smell is Reduced in PD Mckinnon et al. Int l J Neurosci 10
20 Importance of Smell Testing Patients with PD lose their sense of smell before motor signs develop Smell testing may be used to identify of group of people that do not have PD but are increased risk for developing PD
21 REM Sleep Behavior Disorder
22 REM Sleep Behavior Disorder Adler et al. Park Rel Dis 11
23 Autonomic Symptoms
24 Autonomic Symptoms Damian et al. Park Rel Dis 12
25 EEG and EMG Testing
26 TISSUE DIAGNOSIS OF PARKINSON S DISEASE
27
28 GI regions assessed for phosphorylated a-synuclein staining Beach et al. Acta Neuropathol 10
29 Submandibular Gland
30 Background Lewy-type phosphorylated a-synuclein (LTS) staining is found in submandibular glands of autopsied PD cases 1,2 28/28 PD post-mortem whole submandibular glands were found to have LTS, none found in control, PSP, incidental Lewy Body cases 3 17/19 needle core biopsies of thawed PD postmortem submandibular gland had LTS 3 1 Beach et al. Acta Neuropathol 10; 2 Del Tredici et al. Acta Neuropathol 10; 3 Beach et al. J Neuropathol Exp Neurol 13
31 Two SMG Needle Core Biopsy Studies 1 st study: 15 PD > 5 year disease duration, responsive to dopaminergic medications 2 nd study: 25 PD < 5 yrs disease duration and 10 controls. All PD DaTscan positive Outpatient needle biopsy of the submandibular gland using local anesthetic and palpation to identify gland 3-6 needle cores Adler et al. Neurology 14; Adler et al. Mov Disorders 16
32 Demographics PD > 5 yrs N=15 PD < 5 yrs N=25 Control N=10 Age at biopsy, yrs Disease duration, yrs Mean = 11.8 (6-17) Mean = 2.6 ( ) Male 6 (40%) 16 (64%) 3 (30%) N/A UPDRS motor score, mean Motor fluctuations 13 0 Adler et al. Neurology 14; Adler et al. Mov Disorders 16
33 Results PD > 5 yrs N=15 PD < 5 yrs N=25 Control N=10 Insufficient Tissue LTS positive 9/12 (75%) 14/19 (74%) 2/9 (22%) Side effects 5/15 (33%) Mainly swelling or bruising 27/35 (77%) 22-swelling, 5- bruising 3- sore throat Adler et al. Neurology 14; Adler et al. Mov Disorders 16
34 SMG biopsy in RBD and PD 21 irbd, 24 PD, 26 controls Ultrasound guidance of 45 cases and 7 controls- still < 50% had glandular tissue 8/9 (89%) RBD and 8/12 (67%) PD positive No controls were positive SE: 11/52 pain, 9/52 subcutaneous hematoma Vilas et al. Lancet Neurol 16
35 Conclusions- SMG Biopsy Submandibular gland biopsies may be useful as a diagnostic test for LTS in living PD patients with early and advanced disease The lack of 100% positivity may be 2 o to insufficient tissue acquisition with a needle biopsy, as found in our autopsy study inaccuracy of a clinical diagnosis of PD Biopsies are safe and well tolerated
36 Value of Submandibular Gland Biopsy Given inaccuracy of clinical dx, especially early, PD tissue bx would confirm dx Improve clinical trial entry, higher observed effect size, reduce number of patients needed Serve as gold standard, short of autopsy, for validation of other candidate biomarkers
37 Current Studies
38 S4 Systemic Synuclein Sampling Study Biopsies of SMG, skin, colon Spinal tap, blood, saliva One time for each of these Determine what biopsy or tissue would be best to make the diagnosis of PD and/or follow the progress of PD MJFF funded, multi-site Amy Duffy (Research Coordinator) ;
39 Weight Loss in PD Examine factors that may lead to weight loss Mainly interested in possible bacteria in the small intestine Must have had at least a 10% weight loss since developed PD One time visit for a breath test Amy Duffy (Research Coordinator) ; duffy.amy@mayo.edu
40 JZP-110 for Daytime Sleepiness Crossover study All patients will receive the experimental drug and the placebo Details are to come Amy Duffy (Research Coordinator) ;
41 Sanofi ACT for Early PD Must be a carrier of a GBA mutation GZ/SAR vs placebo given for 1 year then a 2 year follow-up study where all will get the study drug Study should be starting soon Galasky.Irene@mayo.edu
42 Other Trials in the Valley SURE-PD3 at BNI Oral inosine to slow PD. PD < 3 yrs on no dopamine meds PF for early and advanced at BNI Freezing and the 6 minute walk test at A.T.Still Univ
43 What Can You Do? Volunteers from Maricopa County, AZ are leading the way to finding these answers!!! Call Amy Duffy at Mayo Clinic Call Kathy Jo Davis at BSHRI
44 National Brain and Tissue Resource for Parkinson s Disease and Related Disorders Funded by NINDS, Michael J. Fox Foundation, Arizona Biomedical Research Commission, International Essential Tremor Foundation BANNER SUN HEALTH RESEARCH INSTITUE MAYO CLINIC ARIZONA Tom Beach, MD, PhD Charles Adler, MD, PhD David Shprecher, DO Ed Zamrini, MD Erika Driver-Dunckley, MD John Caviness, MD Kathy Jo Davis Lucia Sue BARROW NEUROLOGIC Christi Belden, PhD Geidy Serrano, PhD Marwan Sabbagh, MD Holly Shill, MD Bruce Peterson Shyamal Mehta, MD, PhD Joe Hentz, MS
How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.
How to Diagnose Early (Prodromal) Lewy Body Dementia Ian McKeith MD, FRCPsych, F Med Sci. Parkinson s Disease Lewy Body Disease Time PD Dementia Lewy Body Dementias Dementia with Lewy Bodies (DLB) Diagnostic
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationUSING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research
USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE The Michael J. Fox Foundation for Parkinson s Research MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission We are
More informationLearnings from Parkinson s disease: Critical role of Biomarkers in successful drug development
Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development Ken Marek Coalition Against Major Diseases and FDA 2014 Annual Scientific Workshop Oct 2014 Disclosure Co-founder
More informationFinal Scientific Progress Report
CUREPSP Final Scientific Progress Report Tau in Peripheral Tissues of PSP and CBD. Brittany Dugger, PhD; University of California San Francisco Specific Aim: Using immunohistochemical methods on autopsy
More informationResearch Article Essential Tremor in the Elderly and Risk for Dementia
Neurodegenerative Diseases, Article ID 328765, 5 pages http://dx.doi.org/10.1155/2014/328765 Research Article Essential Tremor in the Elderly and Risk for Dementia Holly A. Shill, 1 Joseph G. Hentz, 2
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationFOUNDATION OF UNDERSTANDING PARKINSON S DISEASE
FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE DEE SILVER M.D MOVEMENT DISORDER SPECIALIST MEDICAL DIRECTOR -- PARKINSON ASSOCIATION OF SAN DIEGO 1980 TO PRESENT SCRIPPS MEMORIAL HOSPITAL, LA JOLLA CA.
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationNon-motor symptoms as a marker of. Michael Samuel
Non-motor symptoms as a marker of progression in Parkinson s s disease Michael Samuel London, UK 1 Definitions and their problems Non-motor symptoms as a marker of progression Non-motor symptoms (NMS)
More informationWHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS. MJFF Third Thursdays Webinar March 17, 2016
WHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS MJFF Third Thursdays Webinar March 17, 2016 WHAT WE LL COVER TODAY How is Parkinson s misdiagnosed? How is Parkinson s diagnosed today? Can we use DaTscan
More informationNovel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology
Novel Targets of disease modifying therapy for Parkinson disease David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Disclosures Dr. Standaert has served as a paid consultant
More informationThe Parkinson s You Can t See
The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?
More information2017 Phoenix Clinical Research Fair Program of Events
2017 Phoenix Clinical Research Fair Program of Events From 8:45 a.m. Check-in Second Floor of the Conference Center 8:45 a.m. 1:00 p.m. Trial Exhibition Second Floor of the Conference Center 9:30 a.m.
More informationThe Latest Research in Parkinson s Disease. Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo
The Latest Research in Parkinson s Disease Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo OR.. Rethinking Parkinson s Disease Lawrence Elmer, MD, PhD Professor, Dept. of Neurology
More informationSurgical Management of Parkinson s Disease
Surgical Management of Parkinson s Disease Shyamal H. Mehta MD, PhD Assistant Professor of Neurology, Movement Disorders Division Mayo Clinic College of Medicine Mayo Clinic, Arizona 2016 MFMER slide-1
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationLa neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali
La neurosonologia Nelle patologie degenerative e vascolari cerebrali Andrea Pilotto Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative Prof. Daniela Berg Department of Neurodegeneration
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More informationWhat are the Latest Treatment Advances in Parkinson disease
What are the Latest Treatment Advances in Parkinson disease Fatta B. Nahab, M.D. Associate Professor of Neurosciences Director, Functional Imaging of Neurodegenerative Disorders Lab Overview Recently approved
More informationChange the size of any window by dragging the lower left corner. Use controls
Early Detection of Parkinson s s Disease Change the size of any window by dragging the lower left corner. Use controls in top right corner to close or maximize each window Use text box at bottom left to
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationThe Parkinson Progression Marker Initiative (PPMI) WW-ADNI July
The Parkinson Progression Marker Initiative (PPMI) WW-ADNI July 15 2011 Rationale for PPMI: Challenges of disease-modifying trials Disease modifying PD therapeutics remain a major unmet need A major obstacle
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Assistant Professor of Neurology and Psychiatry University of Colorado Denver Goals 1) What are the most common non-motor
More informationDamian, Anne Mariam. The University of Arizona.
The Montreal Cognitive Assessment and the Mini- Mental State Examination as Screening Instruments for Cognitive Impairment: Item Analyses and Threshold Scores Item Type Thesis Authors Damian, Anne Mariam
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationClinical Trial Glossary
Clinical Trial Glossary Adverse event An unfavorable change in health that can occur during a clinical trial or study or within a certain time period after. These can range from mild (e.g., nausea) to
More informationMoving Treatment Earlier Disease Modification in Early PD
Moving Treatment Earlier Disease Modification in Early PD Ron Postuma Montreal General Hospital McGill University Disclosures: - Grants: Fonds de la Recherche en Sante Quebec, Canadian Institute of Health
More informationEarly Clinical Features of Parkinson s Disease and Related Disorders. Dr. Alastair Noyce
1 Specialist Registrar in Neurology, London Deanery Parkinson s UK Doctoral Research Fellow Project lead for PREDICT-PD Declarations Salary: Parkinson's UK, Barts and the London NHS Trust Grants: Parkinson's
More informationNon-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative
Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative Samay Jain, MD MSc Seo Young Park, PhD University of Pittsburgh Department of Neurology and Center for Research
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationThe Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone
The Role of DOPAL in Parkinson s Disease Karenee Demery Copyright May, 2015, Karenee Demery and Koni Stone Parkinson s disease is an incurable, neurodegenerative disease. The cause is still not fully understood.
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More information2/5/2015. Sensitive: Discriminative: Simple Inexpensive. Example of a good biomarker: blood tests, CSF test but they are not discriminative for PD
Jeffrey H. Kordower, Ph.D.. Department of Neurological Sciences Rush University Medical Center Sensitive: Discriminative: Simple Inexpensive Example of a good biomarker: blood tests, CSF test but they
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationPD ExpertBriefing: What s in the Parkinson s Pipeline
PD ExpertBriefing: What s in the Parkinson s Pipeline Presented by: David G. Standaert, M.D., Ph.D. Professor of Neurology Director, Center for Neurodegeneration and Experimental Therapeutics University
More informationBehavioral Aspects of Parkinson s Disease
Behavioral Aspects of Parkinson s Disease Joseph H. Friedman, MD Director, Movement Disorders Program Butler Hospital Dept of Neurology Alpert Medical School of Brown University 1 Disclosures Drugs will
More informationUDS version 3 Summary of major changes to UDS form packets
UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationThe Spectrum of Age-Associated Astroglial Tauopathies. Dennis W. Dickson MD Department of Neuroscience Mayo Clinic, Jacksonville, FL
The Spectrum of Age-Associated Astroglial Tauopathies Dennis W. Dickson MD Mayo Clinic, Jacksonville, FL Thorn-shaped astrocytes TSA were first reported by Ikeda (1995), as tau-positive astrocytes in various
More informationNon-Motor Symptoms of Parkinson s Disease
Non-Motor Symptoms of Parkinson s Disease Samantha Holden, MD University of Colorado Movement Disorders MOTOR SYMPTOMS Rigidity Bradykinesia Tremor Gait Imbalance NON-MOTOR SYMPTOMS Dementia Urinary frequency
More informationRecent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
More informationProfessor K Ray Chaudhuri
Centre of excellence Parkinson s Care and Research The Spectrum of Non Motor Symptoms in Parkinson s Evolving concepts Professor K Ray Chaudhuri St Thomas Hospital Guy s Hospital National Parkinson Foundation
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationParkinson s Foundation
Parkinson s Foundation PD ExpertBriefing: Diagnosis PD, Now What? Managing the First Few Years with Parkinson s Led By: Suketu Khandhar, M.D., Medical Director at Kaiser Permanente Northern California
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationTHIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY?
THIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY? THURSDAY MARCH 14, 2019 REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA AMERICAN
More informationRedefinition of Parkinson s Disease
Redefinition of Parkinson s Disease Authors Eva Schäffer 1, Daniela Berg 1, 2 Affiliations 1 Department of Neurology, Christians-Albrechts-University of Kiel, Kiel, Germany 2 Department of Neurodegeneration,
More informationDEMENS MED LEWYLEGEMER OG PARKINSON DEMENS
DEMENS MED LEWYLEGEMER OG PARKINSON DEMENS Dag Årsland Regionalt senter for eldremedisin og samhndling (SEAM), Stavanger Dept of Old age psychiatry, Institute of Psychiatry, Psychology and Neuroscience,
More informationThe Search for a Peripheral Biopsy Indicator of a-synuclein Pathology for Parkinson Disease
J Neuropathol Exp Neurol Vol. 76, No. 1, January 2017, pp. 2 15 doi: 10.1093/jnen/nlw103 REVIEW ARTICLE The Search for a Peripheral Biopsy Indicator of a-synuclein Pathology for Parkinson Disease John
More informationParkinson s National Audit 2015
+ Parkinson s National Audit 2015 Audit team Dr Dipen Gandecha, Specialty Doctor Claire Andrew, Parkinson s Disease Practitioner Dr William Wareing, Registrar Victoria Peers, Clinical Audit Officer Project
More informationPietro Cortelli. IRCCS Istituto delle Scienze Neurologiche di Bologna DIBINEM, Alma Mater Studiorum - Università di Bologna
Pietro Cortelli IRCCS Istituto delle Scienze Neurologiche di Bologna DIBINEM, Alma Mater Studiorum - Università di Bologna HYSTORY 1900 description of OPCA (Dejerine, Thomas) 1960 description of Shy-Drager
More informationPPMI Status Update. Ken Marek. WW-ADNI July 11, 2013
PPMI Status Update Ken Marek WW-ADNI July 11, 2013 Disclosure Co-founder on Molecular Neuroimaging LLC PET and SPECT imaging services Consultant BMS, GEHC, Lilly, Merck, Navidea, Piramal Pfizer, Sanofi,
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationUpdate on Parkinson s disease and other Movement Disorders October 2018
Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie
More informationPPMI Data Overview. Christopher S. Coffey The University of Iowa. PPMI Investigators Meeting May 13-14, 2015 New York, NY
PPMI Data Overview Christopher S. Coffey The University of Iowa PPMI Investigators Meeting May 13-14, 2015 New York, NY Source of data for this presentation: Information comes from: Tables produced for
More informationDirector, Movement Disorders Research Banner Good Samaritan Medical Center, Phoenix, Arizona. June 2003
Curriculum Vitae JOHAN E. S. SAMANTA, M.D. Movement Disorders Neurologist Diplomate ofthe ABPN 2610 N 3 rd St, Suite A Phoenix, AZ 85004 Phone: 602-277-2228 Fax: 602-265-9494 Tax ID: 86-1025375 CURRENT
More informationPrion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice
Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice Nolwen L. Rey, PhD Patrik Brundin s Laboratory, Van Andel Research Institute Grand Rapids, Michigan, USA 15th Annual
More informationParkinson s Progression Markers Initiative (PPMI) John Q. Trojanowski, M.D., Ph.D.
Parkinson s Progression Markers Initiative (PPMI) John Q. Trojanowski, M.D., Ph.D. Parkinson s Progression Marker Initiative NINDS Udall Center of Excellence For Parkinson s Disease Research, NIA Alzheimer
More informationUpdate on functional brain imaging in Movement Disorders
Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF
More informationClinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA
Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal
More information! slow, progressive, permanent loss of neurologic function.
UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation
More informationComprehensive Approach to DLB Management
Comprehensive Approach to DLB Management Bradley F. Boeve, MD Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Comprehensive Approach to DLB Management Disclosures
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationPPMI Genetics Cohorts
PPMI Genetics Cohorts Ken Marek PPMI Genetics Kickoff Sept 16, 2013 New York, NY PPMI Genetic Cohort/Registry Symptomatic Neuron Function Prodromal P-PPMI Gen P-PPMI PPMI Diagnosis PPMI- Gen 2 PPMI-Genetics
More informationKelly Mills, MD, MHS Johns Hopkins Parkinson s Disease and Movement Disorders Center
Kelly Mills, MD, MHS Johns Hopkins Parkinson s Disease and Movement Disorders Center Disclosures Research support from St. Jude / Abbott Funding National Institutes of Health / NINDS Parkinson Foundation
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationGenetic Parkinson s studying the few to treat the many
Edinburgh Talk 01.12.12 Genetic Parkinson s studying the few to treat the many Miratul Muqit, Wellcome Trust Intermediate Fellow, Honorary Consultant Neurologist, MRC Protein Phosphorylation Unit, University
More informationUpdate on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016
Update on the DLB Module ADC Directors Meeting Baltimore, MD October 14-15, 2016 Committee Members James Galvin, Florida Atlantic University Chair James Leverenz Cleveland Clinic Brad Boeve Mayo Clinic
More informationSTUDIES TO SLOW OR STOP PARKINSON S DISEASE. MJFF Third Thursdays Webinar October 15, 2015
STUDIES TO SLOW OR STOP PARKINSON S DISEASE MJFF Third Thursdays Webinar October 15, 2015 WHAT WE LL COVER TODAY What are the varied approaches to stop Parkinson s? How can our immune system help fight
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationThe Marmoset Monkey as Model for Neurological Disorders
The Marmoset Monkey as Model for Neurological Disorders Jan Langermans and Ingrid Philippens From Laboratory to Clinic Disease models neuroscience: Parkinson, Sleep, Stress, Alzheimer, MS MS Models: rhmog
More informationParkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute
Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease 2 nd most common neurodegenerative disorder Peak age at onset is 60 years
More informationModeling Parkinson s disease: systems to test gene-environment interactions
Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)
More informationUnited Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline
United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline REV 3/24/09 The UCNS Geriatric Neurology examination was established to determine the level of competence
More informationUsing Sources in the GDP
Using Sources in the GDP The following are five examples of sources that you may encounter while working on your GDP project. The information contained in each of these sources (shown by screen shot) was
More informationPREDICT-PD: An Online Approach to Prospectively Identify Risk Indicators of Parkinson s Disease
RESEARCH ARTICLE PREDICT-PD: An Online Approach to Prospectively Identify Risk Indicators of Parkinson s Disease Alastair J. Noyce, MRCP, PhD, 1,2 Lea R Bibo, MSc, MRes, 1 Luisa Peress, BSc, 2 Jonathan
More informationBiomedical Technology Research Center 2011 Workshop San Francisco, CA
Diffusion Tensor Imaging: Parkinson s Disease and Atypical Parkinsonism David E. Vaillancourt court1@uic.edu Associate Professor at UIC Departments t of Kinesiology i and Nutrition, Bioengineering, and
More informationWelcome to today s webinar
Welcome to today s webinar We will begin the webinar at 2:00 p.m. Eastern All attendee lines are automatically muted. This webinar is being recorded and will be posted on LBDA s Youtube page. Throughout
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationDesigning patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials
1 Informative series of workshops featuring emerging trends in medical technology regulatory science, MDIC projects and subject matter experts sharing perspectives, progress and opportunities. Designing
More informationParkinson s Founda.on
Parkinson s Founda.on PD ExpertBriefing: Sleep and Parkinson s Led By: Aleksandar Videnovic, M.D., M.Sc. Associate Professor of Neurology; Director, MGH Program on Sleep, Circadian Biology and NeurodegeneraDon
More informationDIFFERENTIAL DIAGNOSIS SARAH MARRINAN
Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential
More informationPD ExpertBriefing: Fatigue, Sleep Disorders and Parkinson's Disease. Presented By:
PD ExpertBriefing: Fatigue, Sleep Disorders and Parkinson's Disease Presented By: Joseph H. Friedman, M.D. Movement Disorders Program Butler Hospital Department of Neurology Alpert Medical School of Brown
More informationCAREGIVER SUMMIT. The PD You Can't See: Dealing with Non-Motor Symptoms. Kaitlyn Roland, PhD. Sponsored by:
CAREGIVER SUMMIT The PD You Can't See: Dealing with Non-Motor Symptoms Kaitlyn Roland, PhD Sponsored by: Cognition VS Dementia Memory Executive Function Attention Bradyphrenia Visuospatial Language Hallucinations
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationUpdate on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016
Update on the DLB Module ADC Directors Meeting Baltimore, MD October 14-15, 2016 Committee Members James Galvin, Florida Atlantic University (Chair) James Leverenz Cleveland Clinic Brad Boeve Mayo Clinic,
More information